Valuation: MacroGenics, Inc.

Market Cap 235M 207M 192M 176M 331M 22.65B 336M 2.28B 891M 11.13B 883M 864M 38.5B P/E 2026 *
-5.52x
P/E 2027 * -2.42x
Enterprise Value 235M 207M 192M 176M 331M 22.65B 336M 2.28B 891M 11.13B 883M 864M 38.5B EV / Sales 2026 *
1.43x
EV / Sales 2027 * 2.5x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day-7.73%
1 week-17.59%
Current month-19.91%
1 month-23.08%
3 months+15.99%
6 months+102.19%
Current year+129.81%
1 week 3.36
Extreme 3.36
4.61
1 month 3.36
Extreme 3.36
5.06
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
28.09
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
19/5/26 Free

Founder

25,750 0.0405%
19/5/26 Free

Director

25,750 0.0405%
19/5/26 Free

Chairman

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
-7.73%-17.59%+116.37%-21.11% 235M
+0.93%+6.97%+59.60%+69.78% 57.28B
-1.92%+6.03%+40.64%+80.66% 54.99B
-0.46%-1.29%+2.86%+425.15% 23.18B
-2.97%-2.35%-22.53%-15.34% 22.59B
-0.36%+5.73%+24.13%-7.02% 20.46B
-1.34%+0.51%+26.03%-28.68% 17.56B
-1.44%+5.67%+38.77%+565.80% 15.67B
-1.30%-5.02%+170.77%+310.94% 14.46B
-0.50%-0.98%+21.43%+179.36% 13.92B
Average -1.71%-0.61%+47.81%+155.95% 24.03B
Weighted average by Cap. -0.88%+2.08%+39.78%+137.91%

Financials

2026 *2027 *
Net sales 164M 144M 134M 123M 232M 15.83B 235M 1.59B 623M 7.78B 617M 604M 26.91B 94.26M 82.79M 76.99M 70.65M 133M 9.08B 135M 914M 357M 4.46B 354M 346M 15.43B
Net income -18.31M -16.08M -14.95M -13.72M -25.78M -1.76B -26.18M -178M -69.37M -867M -68.72M -67.24M -3B -127M -112M -104M -95.22M -179M -12.23B -182M -1.23B -481M -6.01B -477M -467M -20.8B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
24/07/26 US$3.700 -7.73% 2,653,931
23/07/26 US$4.010 -6.74% 575,820
22/07/26 US$4.300 -5.29% 502,498
21/07/26 US$4.540 +5.09% 648,393
20/07/26 US$4.320 -3.79% 603,167
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.700USD
Average target price
6.750USD
Spread / Average Target
+82.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock